Ngā hua rapu kaituhi

1

Systemic mast cell disease: A clinical and hematopathologic study of 26 cases mā Thomas A. Webb, Chin‐Yang Li, Lung T. Yam

I whakaputaina 1982

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes mā Ronald S. Go, Chin‐Yang Li, Ayalew Tefferi, Robert L. Phyliky

I whakaputaina 2001

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Treatment of Systemic Mast-Cell Disease with Cladribine mā Ayalew Tefferi, Chin‐Yang Li, Joseph H. Butterfield, H. Clark Hoagland

I whakaputaina 2001

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Carta

Tiaki ki tētahi rārangi

I tiakina i:
4

Epstein-Barr virus infection in Richter's transformation mā Stephen M. Ansell, Chin‐Yang Li, Ricardo V. Lloyd, Robert L. Phyliky

I whakaputaina 1999

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2... mā Ken Hong Lim, Animesh Pardanani, Joseph H. Butterfield, Chin‐Yang Li, Ayalew Tefferi

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

Systemic Mast Cell Disease mā William D. Travis, Chin‐Yang Li, Erik J. Bergstralh, Lung T. Yam, Ronald G. Swee

I whakaputaina 1988

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study mā David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Leigh A. Gray, Ayalew Tefferi

I whakaputaina 2002

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Significance of systemic mast cell disease with associated hematologic disorders mā William D. Travis, Chin‐Yang Li, Lung T. Yam, Erik J. Bergstralh, Ronald G. Swee

I whakaputaina 1988

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases mā Ruben A. Mesa, Chin‐Yang Li, Rhett P. Ketterling, Georgene Schroeder, Ryan A. Knudson, Ayalew Tefferi

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia mā Ayalew Tefferi, Ruben A. Mesa, Georgene Schroeder, Curtis A. Hanson, Chin‐Yang Li, Gordon W. Dewald

I whakaputaina 2001

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Validation and comparison of contemporary prognostic models in primary myelofibrosis mā Ayalew Tefferi, Jocelin Huang, Susan M. Schwager, Chin‐Yang Li, Wenting Wu, Animesh Pardanani, Ruben A. Mesa

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Risk factors for leukemic transformation in patients with primary myelofibrosis mā Jocelin Huang, Chin‐Yang Li, Ruben A. Mesa, Wentling Wu, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults mā Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin‐Yang Li, Ayalew Tefferi

I whakaputaina 2010

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Thalidomide treatment in myelofibrosis with myeloid metaplasia mā Michelle A. Elliott, Ruben A. Mesa, Chin‐Yang Li, C. Christopher Hook, Stephen M. Ansell, Ralph Levitt, Susan M. Geyer, Ayalew Tefferi

I whakaputaina 2002

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates mā Ayalew Tefferi, Terra L. Lasho, Susan M. Schwager, David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Martha Wadleigh, D. Gary Gilliland

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903 mā Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark R. Litzow, Elisabeth Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors mā Ken-Hong Lim, Ayalew Tefferi, Terra L. Lasho, Christy Finke, Mrinal M. Patnaik, Joseph H. Butterfield, Rebecca F. McClure, Chin‐Yang Li, Animesh Pardanani

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia mā Jaya Kittur, Ryan A. Knudson, Terra L. Lasho, Christy Finke, Naseema Gangat, Alexandra P. Wolanskyj, Chin‐Yang Li, Wenting Wu, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia mā Ayalew Tefferi, Shireen Sirhan, Terra L. Lasho, Susan M. Schwager, Chin‐Yang Li, David Dingli, Alexandra P. Wolanskyj, David P. Steensma, Ruben A. Mesa, D. Gary Gilliland

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia mā Animesh Pardanani, Stephanie R. Brockman, Sarah F. Paternoster, Heather C. Flynn, Rhett P. Ketterling, Terra L. Lasho, Ching-Liang Ho, Chin‐Yang Li, Gordon W. Dewald, Ayalew Tefferi

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Systemic mast cell disease: A clinical and hematopathologic study of 26 cases mā Thomas A. Webb, Chin‐Yang Li, Lung T. Yam

Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes mā Ronald S. Go, Chin‐Yang Li, Ayalew Tefferi, Robert L. Phyliky

Treatment of Systemic Mast-Cell Disease with Cladribine mā Ayalew Tefferi, Chin‐Yang Li, Joseph H. Butterfield, H. Clark Hoagland

Epstein-Barr virus infection in Richter's transformation mā Stephen M. Ansell, Chin‐Yang Li, Ricardo V. Lloyd, Robert L. Phyliky

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2... mā Ken Hong Lim, Animesh Pardanani, Joseph H. Butterfield, Chin‐Yang Li, Ayalew Tefferi

Systemic Mast Cell Disease mā William D. Travis, Chin‐Yang Li, Erik J. Bergstralh, Lung T. Yam, Ronald G. Swee

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study mā David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Leigh A. Gray, Ayalew Tefferi

Significance of systemic mast cell disease with associated hematologic disorders mā William D. Travis, Chin‐Yang Li, Lung T. Yam, Erik J. Bergstralh, Ronald G. Swee

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases mā Ruben A. Mesa, Chin‐Yang Li, Rhett P. Ketterling, Georgene Schroeder, Ryan A. Knudson, Ayalew Tefferi

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia mā Ayalew Tefferi, Ruben A. Mesa, Georgene Schroeder, Curtis A. Hanson, Chin‐Yang Li, Gordon W. Dewald

Validation and comparison of contemporary prognostic models in primary myelofibrosis mā Ayalew Tefferi, Jocelin Huang, Susan M. Schwager, Chin‐Yang Li, Wenting Wu, Animesh Pardanani, Ruben A. Mesa

Risk factors for leukemic transformation in patients with primary myelofibrosis mā Jocelin Huang, Chin‐Yang Li, Ruben A. Mesa, Wentling Wu, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults mā Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin‐Yang Li, Ayalew Tefferi

Thalidomide treatment in myelofibrosis with myeloid metaplasia mā Michelle A. Elliott, Ruben A. Mesa, Chin‐Yang Li, C. Christopher Hook, Stephen M. Ansell, Ralph Levitt, Susan M. Geyer, Ayalew Tefferi

The <i>JAK2</i><sup>V617F</sup> tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates mā Ayalew Tefferi, Terra L. Lasho, Susan M. Schwager, David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Martha Wadleigh, D. Gary Gilliland

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903 mā Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark R. Litzow, Elisabeth Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors mā Ken-Hong Lim, Ayalew Tefferi, Terra L. Lasho, Christy Finke, Mrinal M. Patnaik, Joseph H. Butterfield, Rebecca F. McClure, Chin‐Yang Li, Animesh Pardanani

Clinical correlates of <i>JAK2</i>V617F allele burden in essential thrombocythemia mā Jaya Kittur, Ryan A. Knudson, Terra L. Lasho, Christy Finke, Naseema Gangat, Alexandra P. Wolanskyj, Chin‐Yang Li, Wenting Wu, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi

Ngā hua rapu - Chin‐Yang Li

Systemic mast cell disease: A clinical and hematopathologic study of 26 cases mā Thomas A. Webb, Chin‐Yang Li, Lung T. Yam

Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes mā Ronald S. Go, Chin‐Yang Li, Ayalew Tefferi, Robert L. Phyliky

Treatment of Systemic Mast-Cell Disease with Cladribine mā Ayalew Tefferi, Chin‐Yang Li, Joseph H. Butterfield, H. Clark Hoagland

Epstein-Barr virus infection in Richter's transformation mā Stephen M. Ansell, Chin‐Yang Li, Ricardo V. Lloyd, Robert L. Phyliky

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2... mā Ken Hong Lim, Animesh Pardanani, Joseph H. Butterfield, Chin‐Yang Li, Ayalew Tefferi

Systemic Mast Cell Disease mā William D. Travis, Chin‐Yang Li, Erik J. Bergstralh, Lung T. Yam, Ronald G. Swee

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study mā David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Leigh A. Gray, Ayalew Tefferi

Significance of systemic mast cell disease with associated hematologic disorders mā William D. Travis, Chin‐Yang Li, Lung T. Yam, Erik J. Bergstralh, Ronald G. Swee

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases mā Ruben A. Mesa, Chin‐Yang Li, Rhett P. Ketterling, Georgene Schroeder, Ryan A. Knudson, Ayalew Tefferi

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia mā Ayalew Tefferi, Ruben A. Mesa, Georgene Schroeder, Curtis A. Hanson, Chin‐Yang Li, Gordon W. Dewald

Validation and comparison of contemporary prognostic models in primary myelofibrosis mā Ayalew Tefferi, Jocelin Huang, Susan M. Schwager, Chin‐Yang Li, Wenting Wu, Animesh Pardanani, Ruben A. Mesa

Risk factors for leukemic transformation in patients with primary myelofibrosis mā Jocelin Huang, Chin‐Yang Li, Ruben A. Mesa, Wentling Wu, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults mā Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin‐Yang Li, Ayalew Tefferi

Thalidomide treatment in myelofibrosis with myeloid metaplasia mā Michelle A. Elliott, Ruben A. Mesa, Chin‐Yang Li, C. Christopher Hook, Stephen M. Ansell, Ralph Levitt, Susan M. Geyer, Ayalew Tefferi

The <i>JAK2</i><sup>V617F</sup> tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates mā Ayalew Tefferi, Terra L. Lasho, Susan M. Schwager, David P. Steensma, Ruben A. Mesa, Chin‐Yang Li, Martha Wadleigh, D. Gary Gilliland

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903 mā Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark R. Litzow, Elisabeth Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors mā Ken-Hong Lim, Ayalew Tefferi, Terra L. Lasho, Christy Finke, Mrinal M. Patnaik, Joseph H. Butterfield, Rebecca F. McClure, Chin‐Yang Li, Animesh Pardanani

Clinical correlates of <i>JAK2</i>V617F allele burden in essential thrombocythemia mā Jaya Kittur, Ryan A. Knudson, Terra L. Lasho, Christy Finke, Naseema Gangat, Alexandra P. Wolanskyj, Chin‐Yang Li, Wenting Wu, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi

Ngā utauta rapu:

Ngā marau whai pānga